SXL
RVNC

Summit X LLC’s Revance Therapeutics, Inc. RVNC Stock Holding History

Summit X LLC’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-88,244
Closed -$227K – 237
2024
Q3 		$227K Sell
88,244
-151
-0.2% -$750 0.06% 188
2024
Q2 		$227K Buy
88,395
+54,961
+164% +$188K 0.05% 214
2024
Q1 		$165K Buy
33,434
+16,046
+92% +$95K 0.04% 202
2023
Q4 		$153K Sell
17,388
-257
-1% -$2.11K 0.04% 185
2023
Q3 		$202K Buy
17,645
+858
+5% +$16.5K 0.06% 173
2023
Q2 		$425K Sell
16,787
-1,210
-7% -$37.7K 0.1% 172
2023
Q1 		$580K Buy
+17,997
New +$561K 0.15% 136

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Summit X LLC's RVNC Position: Q4 2024 in Review

Summit X LLC sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 88,244 shares — an estimated $227K sold.

Summit X LLC first reported a position in RVNC in Q1 2023 and held it in 7 quarters. The position peaked at $580K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Summit X LLC reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Summit X LLC sold 88,244 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $227K.
  • Summit X LLC first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 7 quarters.
  • Summit X LLC's Revance Therapeutics, Inc. position peaked at $580K in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Summit X LLC's 13F filing for Q4 2024, filed 7 Feb 2025.